This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Utility of FDG-PET for Radiation Treatment in NSCLC

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2011 by AHS Cancer Control Alberta.
Recruitment status was:  Recruiting
Calgary Health Region
Information provided by (Responsible Party):
AHS Cancer Control Alberta Identifier:
First received: October 4, 2006
Last updated: July 21, 2017
Last verified: August 2011
Patients planned for radical radiation for NSCLC will undergo conventional CT stimulation and also PET/CT scans for definition of radiation target volumes

Condition Intervention
Lung Neoplasms Positron Emission Tomography Procedure: PET/CT scan for RT planning

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Utility of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for Radiation Treatment Planning in Non-Small Cell Lung Cancer (NSCLC)

Resource links provided by NLM:

Further study details as provided by AHS Cancer Control Alberta:

Estimated Enrollment: 50
Study Start Date: October 2006

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Non-small cell lung cancer

Inclusion Criteria:

  • Non-small cell lung cancer to receive radical radiation

Exclusion Criteria:

  • unable to tolerate PET/CT scan
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00385164

Contact: Harold P Lau, MD 403-521-3012

Canada, Alberta
Tom Baker Cancer Centre Recruiting
Calgary, Alberta, Canada, T2N 4N2
Contact: Marilyn David    403-521-3619   
Sponsors and Collaborators
AHS Cancer Control Alberta
Calgary Health Region
Principal Investigator: Harold P Lau, MD AHS Cancer Control Alberta
  More Information

Responsible Party: AHS Cancer Control Alberta Identifier: NCT00385164     History of Changes
Other Study ID Numbers: 20328
Study First Received: October 4, 2006
Last Updated: July 21, 2017

Keywords provided by AHS Cancer Control Alberta:
lung neoplasms
positron emissions tomography
radiotherapy planning

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases processed this record on September 19, 2017